Biotech company focusing on next-generation vaccines
Founded in 1987, Novavax develops next-generation protein-based vaccines using recombinant nanoparticle technology, including candidates for COVID-19, influenza, and RSV.
Данные отсутствуют
FAQ отсутствуют.